Literature DB >> 9681705

The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity--the experience of the Lombardy Dialysis Registry.

F Locatelli, F Conte, D Marcelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9681705     DOI： 10.1093/ndt/13.7.1642

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  14 in total

1.  The care of patients with chronic kidney disease.

Authors:  Annamaria T Kausz; Andrew S Levey
Journal:  J Gen Intern Med       Date:  2002-08       Impact factor: 5.128

2.  Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease.

Authors:  Alan S Go; Nisha Bansal; Malini Chandra; Phenius V Lathon; Stephen P Fortmann; Carlos Iribarren; Chi-Yuan Hsu; Mark A Hlatky
Journal:  J Am Coll Cardiol       Date:  2011-10-04       Impact factor: 24.094

3.  Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients.

Authors:  Alexander Kainz; Bernd Mayer; Reinhard Kramar; Rainer Oberbauer
Journal:  Nephrol Dial Transplant       Date:  2010-05-26       Impact factor: 5.992

4.  Anaemia predicts cardiovascular events in patients with stable coronary artery disease.

Authors:  E Lips̆ic; F W Asselbergs; P van der Meer; R A Tio; A A Voors; W H van Gilst; F Zijlstra; D J van Veldhuisen
Journal:  Neth Heart J       Date:  2005-08       Impact factor: 2.380

5.  Ethnicity, socioeconomic status, and attainment of clinical practice guideline standards in dialysis patients in the United kingdom.

Authors:  Udaya P Udayaraj; Yoav Ben-Shlomo; Paul Roderick; Retha Steenkamp; David Ansell; Charles R V Tomson; Fergus J Caskey
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 8.237

6.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Authors:  Ryan D Kilpatrick; Cathy W Critchlow; Steven Fishbane; Anatole Besarab; Catherine Stehman-Breen; Mahesh Krishnan; Brian D Bradbury
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

7.  The effect of Vitamin D administration on treatment of anemia in end-stage renal disease patients with Vitamin D deficiency on hemodialysis: A placebo-controlled, double-blind clinical trial.

Authors:  Afsoon Emami Naini; Zahra Parin Hedaiati; Danial Gholami; Amir Hossein Pezeshki; Firoozeh Moinzadeh
Journal:  J Res Med Sci       Date:  2015-08       Impact factor: 1.852

Review 8.  Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?

Authors:  Takeshi Nakanishi; Takahiro Kuragano; Shoji Kaibe; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2012-09-29       Impact factor: 2.801

9.  Decisive indicator for gastrointestinal workup in anemic patients with nondialysis chronic kidney disease.

Authors:  Hyeon Seok Hwang; Youn Mi Song; Eun Oh Kim; Eun Sil Koh; Hye Eun Yoon; Sung Jin Chung; Sang Ju Lee; Yoon Kyung Chang; Chul Woo Yang; Yoon Sik Chang; Suk Young Kim
Journal:  Int J Med Sci       Date:  2012-09-19       Impact factor: 3.738

Review 10.  Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator).

Authors:  Usha Panchapakesan; Siska Sumual; Carol Pollock
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.